Gene
ACVR2A
ACVR2A is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (5), Target-disease associations (461), and 4 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
5 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention ACVR2A. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
The yearly numbers
| Year | Publication mentions | Share of that year |
|---|---|---|
| 2023 | 1 of 11,460 | 0.01% |
| 2022 | 4 of 13,598 | 0.03% |
| 2021 | 8 of 15,045 | 0.05% |
| 2020 | 2 of 14,459 | 0.01% |
| 2019 | 4 of 12,159 | 0.03% |
| 2018 | 3 of 11,854 | 0.03% |
| 2017 | 3 of 11,595 | 0.03% |
| 2016 | 1 of 10,983 | 0.01% |
| 2015 | 4 of 11,395 | 0.04% |
| 2014 | 2 of 10,367 | 0.02% |
Showing 10 of 34 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| Idylla CDx MSI Test | ACVR2A | Biocartis US, Inc. | Colorectal Cancer (CRC) | 2025-08-15 |
Assay-provider ledger (5)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Biocartis | Diagnostic provider | Clinical validation | 3 | September 01, 2025 |
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | July 24, 2021 |
| DAKO (Carpinteria, CA, USA) - IHC antibodies and Autostainer Link 48 platform | Context dependent | Clinical validation | 1 | July 24, 2021 |
| Diatech Pharmacogenetics | Diagnostic provider | Clinical validation | 1 | July 24, 2021 |
| Qiagen (Hilden, Germany) - Mini Amp DNA extraction kit | Reagent supplier | Clinical validation | 1 | July 24, 2021 |
Target-disease associations (461)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX disorder of sex development - skeletal anomalies | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,XX disorder of sex development-skeletal anomalies syndrome | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 461 associations.
Vendor sourcing (3)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1088G>A (p.R363Q) alteration is located in exon 9 (coding exon 9) of the ACVR2A gene. This alteration results from a G to A substitution at nucleotide ... | View ClinVar record SCV003575979.2 |
| Nationwide Children's Hospital | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV007105152.1 |
| Not resolved to an organization | Diagnostics manufacturer | FDA-authorized companion diagnosticFDA companion diagnostic authorization | Microsatellite instability-High (MSI-H) | View FDA device record |
Trial-cited literature (41)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. | BMC medicine | 2024 | 38 |
| Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer. | mAbs | 2023 | 10 |
| Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. | BMC medicine | 2022 | 68 |
| Hereditary Hemorrhagic Telangiectasia: Genetics, Pathophysiology, Diagnosis, and Management. | Journal of clinical medicine | 2022 | 30 |
| Cancer-Related Cachexia: The Vicious Circle between Inflammatory Cytokines, Skeletal Muscle, Lipid Metabolism and the Possible Role of Physical Training. | International journal of molecular sciences | 2022 | 27 |
Showing 5 of 41 papers.
Literature-extracted relations (5)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Insulin Resistance | Disease | associate |
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. | 2021 |
| Neoplasms, Adipose Tissue | Disease | associate |
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. | 2021 |
| Heart Failure | Disease | associate |
Activin type II receptor signaling in cardiac aging and heart failure. | 2019 |
| Muscular Atrophy | Disease | associate |
Activin type II receptor signaling in cardiac aging and heart failure. | 2019 |
| Myositis, Inclusion Body | Disease | associate |
Treatment of sporadic inclusion body myositis with bimagrumab. | 2014 |
Organizations publishing (96)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Novartis Ag | Industry | 4 | 2009 to 2021 |
| Harvard Medical School | Academic | 3 | 2017 to 2024 |
| Assistance Publique – Hôpitaux de Paris | Hospital | 2 | 2015 to 2019 |
| Beth Israel Deaconess Medical Center | Hospital | 2 | 2019 to 2024 |
| Duke University | Academic | 2 | 2010 to 2021 |
Showing 5 of 96 organizations.
Where ACVR2A appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- injury, poisoning or other complication
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
454 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, trial mentions, protein variant mentions, and human sample screening reference.